Pretreated PDX Model Development Services
Focusing on the development of pretreated patient-derived xenograft (PDX) models, Alfa Cytology is committed to precise model customization and stringent quality control, aiming to more accurately replicate human tumor biology, thereby improving predictive power in preclinical studies.
Research Progress of Pretreated PDX Models
Pretreated PDX models are characterized by their ability to mimic the heterogeneity of human cancers, including genetic, histopathological, and treatment response diversity. These models retain the microenvironmental context of the original tumor, providing a more realistic platform for evaluating therapeutic efficacy and toxicity. In preclinical cancer research, the scope of pretreated PDX models is vast. They are used to investigate the efficacy of new drugs, study drug resistance mechanisms, and test combination therapies. These models are particularly useful for cancers with high relapse rates post-treatment, as they can replicate the scenario of recurrent disease.
Fig.1 The brief timeline of milestones in PDX study. (Liu, Y., et al., 2023)
Our Services
With a well-established technology platform of the tumor microenvironment center, Alfa Cytology provides our clients with one-stop solutions for pretreated PDX model development. Our team of expert scientists can tailor the perfect preclinical efficacy testing strategy for your specific research needs.
Pretreated PDX Models Available
Alfa Cytology provides pretreated PDX models for a wide range of human cancer types, including but not limited to:
|
Types of Cancer |
Pretreated PDX Models Available |
| Breast Cancer |
Estrogen Receptor (ER) Positive Models; HER2-Positive Models; Triple-Negative Breast Cancer (TNBC) Models. |
| Colorectal Cancer |
KRAS Mutant Models; Microsatellite Instability (MSI) Models. |
| Pancreatic Cancer |
Gemcitabine-Resistant Models. |
| Prostate Cancer |
Castration-Resistant Prostate Cancer (CRPC) Models. |
| Lung Cancer |
Non-Small Cell Lung Cancer (NSCLC) Models; Small Cell Lung Cancer (SCLC) Models. |
Features of Our Pretreated PDX Models
Alfa Cytology utilizes state-of-the-art technology and expertise to deliver high-quality pretreated PDX models that provide enhanced utility for preclinical cancer research, with key benefits including:
Genetic and Histopathological Fidelity
Genetic, epigenetic and histopathological characteristics of the original patient's tumor are maintained, improving the translatability of preclinical study results.
High Predictive Power
By closely modeling human cancer biology and treatment regimens, these models can reliably predict the efficacy and toxicity of new therapies.
Heterogeneity Representation
The pretreated PDX models encompass the heterogeneity, including intra-tumor and inter-tumor variability, this diversity facilitates the study of different tumor subtypes.
Compatibility with High-Throughput Screening
The high scalability and efficiency of these models allows efficient evaluation of multiple therapeutics and combinations, which accelerates the drug discovery process.
Our Service Process
Tumor Collection and Characterization
Tumor samples are collected from patients and undergo genomic, transcriptomic, and histopathological analyses to ensure accurate representation of the original cancer.
Pretreatment Regimen Application
Design pretreatment programs based on treatment history, including specific medications, dosages, and schedules to replicate patient treatment scenarios.
Xenograft Implantation and Validation
Human tumor tissues are implanted into immunodeficient mice, with subsequent monitoring to confirm successful engraftment and tumor growth.
Therapeutic Testing and Analysis
Novel therapeutic agents and combinations are systematically tested on the pretreated PDX models, with detailed data analysis to evaluate efficacy, toxicity, and resistance mechanisms.
Alfa Cytology provides comprehensive solutions to address key challenges encountered in the field of cancer therapy development. With extensive experience in a wide range of cancer models and expertise in tumors and microenvironments, we are committed to providing our clients with the most accurate in vivo cancer models to meet their precise needs. For inquiries or to learn more about how we can support your cancer research program, please contact us.
Reference
- Liu, Y., et al.; (2023). Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduction and Targeted Therapy, 8(1), 160.
For research use only.
Related Services
